Pulse Medical Listed in KPMG’s Inaugural China Healthcare Tech 50

Release Date:2025-07-02      Source:Guangdong Pulse Medical Technology Co., Ltd.      Author:admin

On July 2, 2025, KPMG, a world-renowned professional services firm, grandly held the launch ceremony of its inaugural China Healthcare Tech 50 Report and Awards Ceremony at the Global Trade Center in Beijing, honoring innovative forces in China’s healthcare technology sector. Pulse Medical was proudly selected for its outstanding innovation and remarkable contributions in the field of cardiovascular medical devices, becoming a model in the industry.

At present, emerging frontiers continue to emerge in the healthcare industry, and breakthroughs are constantly being made in the research on prevention, diagnosis and treatment of major diseases affecting human health. The capability of healthcare technology innovation has become an important indicator of scientific and technological innovation. Against the backdrop of booming global healthcare technology innovation and China’s high priority on scientific and technological innovation for people’s health and well-being, healthcare technology innovation has been elevated to a new height. At this moment, KPMG officially launched the inaugural Healthcare Tech 50 program, aiming to set corporate benchmarks and enhance the influence of Chinese healthcare tech enterprises at home and abroad.

02935b4003531869b083a76f5bbffb2

Based on its evaluation model, detailed materials submitted by enterprises, on-site inspections and other comprehensive factors, the Healthcare Tech 50 ranking generates multi-dimensional scores through expert review and selects 69 listed enterprises after comprehensive assessment.

Guangdong Pulse Medical Technology Co., Ltd. stood out, fully demonstrating its profound strength and unlimited potential in healthcare technology. As a national high-tech enterprise, Guangdong “Little Giant” (Specialized, Sophisticated, Unique, New) enterprise and unicorn-potential enterprise, the company has more than ten years of deep expertise in high-end implantable and interventional cardiovascular medical devices, with fully independent intellectual property rights and a business strategy of import substitution. Faced with the high R&D difficulty and strong interdisciplinary nature of products in minimally invasive interventional therapy for cardiovascular diseases, Pulse Medical has bravely explored and pioneered the innovative R&D model of “clinician-engineer integration”. Leveraging the rich experience of clinicians and the professional capabilities of engineering technicians, the company promotes product optimization and technological innovation, leading the industry in R&D capabilities.

Being selected in the authoritative list of KPMG China’s inaugural Healthcare Tech 50 is not only a high recognition of Pulse Medical’s innovation capability, but also a strong boost for its future development. Amid the booming healthcare technology industry, Pulse Medical will take this opportunity to further deepen its focus in the cardiovascular medical device sector, keep breaking through, contribute more to the transformation and upgrading of China’s healthcare technology industry, and bring more high-quality medical solutions to cardiovascular patients worldwide. Let us look forward to Pulse Medical achieving more glories in the future!